BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Tuesday reported a loss of $86.4 million in its first quarter.
The Boulder, Colorado-based company said it had a loss of $1.63 per share.
The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.80 per share.
The biopharmaceutical company posted revenue of $33.1 million in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $31.7 million.
Clovis shares have risen slightly more than 6% since the beginning of the year. The stock has declined 55% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLVS at https://www.zacks.com/ap/CLVS